Despite numerous advances in treatment options,advanced gastric cancer(AGC)remains a major public health issue and the leading cause of cancer-related deaths.Cisplatin is one of the most effective broadspectrum antica...Despite numerous advances in treatment options,advanced gastric cancer(AGC)remains a major public health issue and the leading cause of cancer-related deaths.Cisplatin is one of the most effective broadspectrum anticancer drugs for AGC and a doublet combination regimen of either cisplatin-based or 5-fluorouracil(5FU)-based chemotherapy is generally used for treatment of patients with AGC.However,there is still no consensus on the best regimen for treating AGC.Recently,various new chemotherapeutic agents,including oral 5FU,taxanes,and irinotecan,have been identified as improving the outcomes for AGC when used as a single agent or in combination with nonplatinum chemotherapy.Nonetheless,it is still unclear whether non-platinum-based chemotherapy is a viable treatment option for patients with AGC.Accordingly,this review focuses on the efficacy and tolerability of non-platinum-based chemotherapy for patients with AGC.展开更多
Although medical treatment has been shown to improve quality of life and prolong survival,no significant progress has been made in the treatment of advanced gastric cancer(AGC)within the last two decades.Thus,the choi...Although medical treatment has been shown to improve quality of life and prolong survival,no significant progress has been made in the treatment of advanced gastric cancer(AGC)within the last two decades.Thus,the choice of optimum standard first-line chemotherapy regimen for AGC remains debatable,and most responses to chemotherapy are partial and of short duration,with a median survival of approximately 7-11 mo and survival at 2 years rarely more than 10%.Recently,remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic pathways.For AGC,several molecular targeting agents are now under evaluation in international randomized studies,and trastuzumab,an anti-HER2 monoclonal antibody,has shown antitumor activity against HER-2 positive AGC.However, this benefit is limited to only about 20%of patients with AGC(patients with HER-2 positive AGC).Therefore,there remains a critical need for both the development of more effective agents and the identification of predictive and prognostic molecular markers to select those patients who will benefit most from specific chemotherapeutic regimens and targeted therapies.展开更多
基金Supported by Kyungpook National University Research Fund,2012
文摘Despite numerous advances in treatment options,advanced gastric cancer(AGC)remains a major public health issue and the leading cause of cancer-related deaths.Cisplatin is one of the most effective broadspectrum anticancer drugs for AGC and a doublet combination regimen of either cisplatin-based or 5-fluorouracil(5FU)-based chemotherapy is generally used for treatment of patients with AGC.However,there is still no consensus on the best regimen for treating AGC.Recently,various new chemotherapeutic agents,including oral 5FU,taxanes,and irinotecan,have been identified as improving the outcomes for AGC when used as a single agent or in combination with nonplatinum chemotherapy.Nonetheless,it is still unclear whether non-platinum-based chemotherapy is a viable treatment option for patients with AGC.Accordingly,this review focuses on the efficacy and tolerability of non-platinum-based chemotherapy for patients with AGC.
文摘Although medical treatment has been shown to improve quality of life and prolong survival,no significant progress has been made in the treatment of advanced gastric cancer(AGC)within the last two decades.Thus,the choice of optimum standard first-line chemotherapy regimen for AGC remains debatable,and most responses to chemotherapy are partial and of short duration,with a median survival of approximately 7-11 mo and survival at 2 years rarely more than 10%.Recently,remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic pathways.For AGC,several molecular targeting agents are now under evaluation in international randomized studies,and trastuzumab,an anti-HER2 monoclonal antibody,has shown antitumor activity against HER-2 positive AGC.However, this benefit is limited to only about 20%of patients with AGC(patients with HER-2 positive AGC).Therefore,there remains a critical need for both the development of more effective agents and the identification of predictive and prognostic molecular markers to select those patients who will benefit most from specific chemotherapeutic regimens and targeted therapies.
